T1	control 38 65	Conventionally Fractionated
T2	intervention 69 110	Hypofractionated Whole-Breast Irradiation
T3	control-participants 425 428	149
T4	intervention-participants 507 510	138
T5	average-age 683 700	40 years or older
T6	eligibility 701 796	with stage 0 to II breast cancer for whom WBI without addition of a third field was recommended
T7	duration 883 923	from February 2011 through February 2014
T8	outcome-Measure 1019 1050	acute and 6-month toxic effects
T9	outcome-Measure 1113 1133	patient-reported QOL
T10	No-of-participants 1365 1368	287
T11	control-participants 1383 1386	149
T12	intervention-participants 1417 1420	138
T13	outcome 1766 1801	physician-reported acute dermatitis
T14	intervention-value 1803 1806	36%
T15	control-value 1810 1813	69%
T16	outcome 1826 1834	pruritus
T17	intervention-value 1836 1839	54%
T18	control-value 1843 1846	81%
T19	outcome 1859 1870	breast pain
T20	intervention-value 1872 1875	55%
T21	control-value 1879 1882	74%
T22	outcome 1895 1912	hyperpigmentation
T23	intervention-value 1914 1916	9%
T24	control-value 1920 1923	20%
T25	outcome 1940 1947	fatigue
T26	intervention-value 1949 1951	9%
T27	control-value 1955 1958	17%
T28	outcome 2053 2090	grade 2 or higher acute toxic effects
T29	intervention-value 2130 2133	47%
T30	control-value 2137 2140	78%
T31	outcome 2208 2215	fatigue
T32	intervention-value 2250 2252	0%
T33	control-value 2256 2258	6%
T34	outcome 2318 2332	lack of energy
T35	intervention-value 2334 2337	23%
T37	outcome 2365 2393	trouble meeting family needs
T38	intervention-value 2395 2397	3%
T39	control-value 2401 2403	9%
T36	control-value 2341 2344	39%
